Ovulation induction agents and cancer;Ovulasyon i̇ndüksiyon ajanlari ve kanser

Journal of the Turkish German Gynecology Association

Volumn 7, Issue 2, 2006, Pages 139-145

  Demirol, Nimet Aygül ^a,b   Güven, Süleyman ^b   Gürgan, Timur ^c  

^a Infertility and Assisted Reproductive Techniques Center   (Turkey)

^b Hacettepe University ^*  (Turkey)

^c HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Assisted; Cancer; Fertility drugs; Infertility; Reproductive techniques

Indexed keywords

CLOMIFENE CITRATE; FERTILITY PROMOTING AGENT; HUMAN MENOPAUSAL GONADOTROPIN;

BREAST CANCER; CANCER RISK; CARCINOGENESIS; CHILDHOOD CANCER; COLON CANCER; DISEASE COURSE; FEMALE INFERTILITY; FOLLOW UP; HISTOLOGY; HUMAN; INFERTILITY; INFERTILITY THERAPY; LONG TERM CARE; MELANOMA; OVARY CANCER; OVULATION INDUCTION; REVIEW; RISK ASSESSMENT; RISK REDUCTION; THYROID CANCER; TREATMENT OUTCOME; TROPHOBLASTIC TUMOR; UTERINE CERVIX CANCER; UTERUS CANCER;

EID: 33746306221     PISSN: 13090399     EISSN: 13090380     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Steptoe P, Edwards R. Birth after reimplantation of a human embryo. Lancet 1978;2:366.
2. Lunenfeld B, Salimovici S, Rabau E, Eshkol A. L'Induction de l'ovulation dans les amenorhées hpophysaries par un traitment de gonadotrophines urinaries menopausiques et de gonadotrophines chroniques. C R Soc Françise de Gynecol 1973;5:1-6.
3. Venn A. Cancer risks associated with the diagnosis of infertility. Best Practice & Research Clinical Obstetrics & Gynaecology 2003;17:343-67.
4. Healy D&Petrucco O. Effective Gynecological Day Surgery. London: Chapman and Hall Medical. 1998.
5. Fathalla MF. Incessant ovulation: A factor in ovarian neoplasia? Lancet 1971;2:163.
6. Henderson BE, Ross RK, Judd HL. Do regular ovulatory cycles increase breast cancer risk? Cancer 1985;56:1206-8.
7. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results From the Women's Health Initiative randomized controlled trial. JAMA 2002;288:321-33.
8. Healy DL. Venn A. Infertility medications and the risk of breast cancer. Fertil Steril 2003;79:852-4.
9. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of breast cancer in a cohort of infertile women. Gynecol Oncol 1996;60:3-7.
10. Modan B, Ron E, Lerner-Geva L, Blumstein T, Menczer J, Rabinovici J, et al. Cancer incidence in a cohort of infertile women. Am J Epidemiol 1998;147:1038-42.
11. Venn A. Watson L, Bruinsma F, Giles G, Healy D. Risk of cancer after use of fertility drugs with in-vitro fertilisation. Lancet 1999;354:1586-90.
12. Klip H, Burger CW, van Leeuwen FE, the OMEGA Project Group, Risk of hormone-related cancers after ovarian stimulation for in-vitro fertilisation in a cohort of 25,152 women. In: Klip H, ed. Long-term health effects of subfertility treatment. Enschede, The Netherlands: PrintPartners Ipskamp BV 2002;55-82.
13. Doyle P, Maconochie N, Beral V, Swerdlow AJ, Tan SL. Cancer incidence following treatment for infertility at a clinic in the UK. Hum Reprod 2002;17:2209-13.
14. Brinton LA, Scoccia B, Moghissi KS, Westhoff CL, Althuis MD, Mabie JE, et al. Breast cancer risk associated with ovulation-stimulating drugs. Hum Reprod 2004;19:2005-13.
15. Braga C, Negri E, La Vecchia C, Parazzini F, Dal Maso L, Franceschi S. Fertility treatment and risk of breast cancer. Hum Reprod. 1996;11:300-3.
16. Burkman RT, Tang MT, Malone KE, Marchbanks PA, McDonald JA, Folger SG, Norman SA, Strom BL, Bernstein L, Ursin G, Weiss LK, Daling JR, Simon MS, Spirtas R. Infertility drugs and the risk of breast cancer: Findings from the National Institute of Child Health and Human Development Women's Contraceptive and Reproductive Experiences Study. Fertil Steril 2003;79:844-51.
17. Arbour L, Narod S, Glendon G, Pollak M, Seymour R, Miner I, et al. In-vitro fertilisation and family history of breast cancer. Lancet 1994;344:610-11.
18. Bolton P. Bilateral breast cancer associated with clomiphene. Lancet 1977;2:1176.
19. Brzezinski A, Peretz T, Mor-Yosef S, Shenker JG. Ovarian stimulation and breast cancer: Is there a link? Gynecol Oncol 1994;52:292-5.
20. Jourdain O, Avril A, Mauriac L, Quenel N, Bussieres E, Roux D et al. Breast cancer and in vitro fertilization. About 32 cases. Eur J Obstet Gynecol Reprod Biol 1996;67:47-52.
21. McGowan L, Parent L, Lednar W, Norris H. The woman at risk of developing ovarian cancer. Gynecol Oncol 1979;7:325-44.
22. Whittemore A, Harris R, Itnyre J. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. J Natl Cancer Inst 1992;136:1184-203.
23. Rossing M, Daling J, Weiss N, Moore D, Self S. Ovarian tumors in a cohort of infertile women. N Engl J Med 1994;331:771-6.
24. Shushan A, Paltiel O, Iscovich J, Elchalal U, Peretz T, Schenker JG. Human menopausal gonadotrophin and the risk of epithelial ovarian cancer. Fertil Steril 1996;65:13-8
25. McClure N, Healy DL, Rogers PAW, Sullivan J, Beaton L, Haning RV, Connolly DT, Robertson DM. Vascular endothelial growth factor as capillary permeability agent in ovarian hyperstimulation syndrome. Lancet 1994;344:235-6.
26. Ness RB, Cramer DW, Goodman MT, Kruger Kjaer S, Mallin K, Mosgaard BJ, et al. Infertility, fertility drugs, and ovarian cancer: A pooled analysis of case-control studies. Am J Epidemiol 2003;155:217-24.
27. Parazzini F, Pelucchi C, Negri E, Franceschi S, Talamini R, Montella M, et al. Use of fertility drugs and risk of ovarian cancer. Hum Reprod 2001; 16:1372-5.
28. Mosgaard BJ, Lidegaard O, Kjaer SK, Schou G, Anderson AN. Infertility, fertility drugs, and invasive ovarian cancer: A case-control study. Fertil Steril 1997;67:1005-12
29. Hahlin M, Crona N, Knutsson F, Janson PO. Human granulosa cell tumor: Stimulation of steroidogenesis by gonadotropins in vitro. Gynecol Oncol 1991;40:201-6.
30. Ken RA, Lozada KL, Abdul-Karim FW, Nadeau JH, Nilson JH. Luteinizing hormone induction of ovarian tumors: Oligogenic differences between mouse strains dictates tumor disposition. Proc Natl Acad Sci USA. 2000;97:383-7.
31. Mikola M, Kero J, Nilson JH, Keri RA, Poutanen M, Huhtaniemi I. High levels of luteinizing hormone analog stimulate gonadal and adrenal tumorigenesis in mice transgenic for the mouse inhibin-alpha-subunit promoter/Simian virus 40 T-antigen fusion gene. Oncogene. 2003;22:3269-78.
32. Franceschi S, La Vecchia C, Negri E, Guarneri S, Montella M, Conti E, et al. Fertility drugs and risk of epithelial ovarian cancer in Italy. Hum Reprod 1994;9:1673-5.
33. Harris R, Whittemore AS, Itnyre J. the Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. III. Epithelial tumors of low malignant potential in white women. Am J Epidemiol 1992;136:1204-11.
34. Parazzini F, Negri E, La Vecchia C, et al. Treatment for fertility and risk of borderline malignancy. Gynecol Oncol 1998;68:226-8.
35. Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and uterine cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304-13.
36. Fishel S, Jackson P. Follicular stimulation for high tech pregnancies: Are we playing it safe? BMJ 1989;299:309-11.
37. Dor J, Lerner-Geva L, Rabinovici J, Chetrit A, Levran D, Lunenfeld B, Mashiach S, Modan B. Cancer incidence in a cohort of infertile women who underwent in vitro fertilization. Fertil Steril 2002;77:324-7.
38. Benshushan A, Paltiel O, Brzezinski A, Tanos V, Barchana M, Shoshani O, Gordon L, Tsur L, Schenker JG. Ovulation induction and risk of endometrial cancer: a pilot study. Eur J Obstet Gynecol Reprod Biol 2001;98:53-7.
39. Althuis MD, Moghissi KS, Westhoff CL, Scoccia B, Lamb EJ, Lubin JH, Brinton LA. Uterine cancer after use of clomiphene citrate to induce ovulation. Am J Epidemiol 2005;161:607-15.
40. Kvale G, Heuch I, Ursin G. Reproductive factors and risk of cancer of the uterine corpus: A prospective study. Cancer Res 1988;48:6217-21.
41. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. In situ and invasive cervical carcinoma in a cohort of infertile women. Fertil Steril 1996;65:19-22.
42. Althuis MD, Scoccia B, Lamb EJ, Moghissi KS, Westhoff CL, Mabie JE, Brinton LA. Melanoma, thyroid, cervical, and colon cancer risk after use of fertility drugs. Am J Obstet Gynecol 2005;193:668-74.
43. Kuppens E, Bergman W, Welvaart K, Bruijn JA, Scheffer E. Multiple primary melanomas in a patient with familial-type DNS during clomiphene-induced pregnancy. Melanoma Res 1992;2:71-4.
44. Fuller PN. Malignant melanoma of the ovary and exposure to clomiphene citrate: A case report and review of the literature. Am J Obstet Gynecol 1999;180:1499-503.
45. Venn A, Watson L, Lumley J, Giles G, King C, Healy D. Breast and ovarian cancer incidence after infertility and in vitro fertilisation. Lancet 1995;346:995-1000.
46. Rossing MA, Daling JR, Weiss NS, Moore DE, Self SG. Risk of cutaneous melanoma in a cohort of infertile women. Melanoma Res 1995;5:123-7.
47. Young P, Purdie D, Jackman L, Molloy D, Green A. A study of infertility treatment and melanoma. Melanoma Res 2001;11:535-41.
48. La Vecchia C, Ron E, Franceschi S, Dal Maso L, Mark SD, Chatenoud L, et al. A pooled analysis of case-control studies of thyroid cancer. III, Oral contraceptives, menopausal replacement therapy and other female hormones. Cancer Causes Control 1999;10:157-66.
49. Burkman RT. Reproductive hormones and cancer: ovarian and colon cancer. Obstet Gynecol Clin North Am 2002;29:527-40.
50. Draper G. The health of our children. In: Register General. Decennial Supplement for England and Wales. London: HMSO; 1995 (chapter 10).
51. Coleman MP, Babb P, Damiecki P, et al. Cancer survival trends in England and Wales. 1971-1995. In: Deprivation and NHS region. London: The Stationnery Office, 1999.
52. Leese HJ, Donnay I, Thompson JG. Human assisted conception; a cautionary tale. Lessons from domestic animals. Hum Reprod 1998;13:184-202.
53. Niemitz EL, Feinberg AP. Epigenetics and assisted reproductive technology: A call for investigation. Am J Hum Genet 2004;74:599-609.
54. Bruinsma F, Venn A, Lancaster P, Speirs A, Healy D. Incidence of cancer born after in vitro fertilisation. Hum Reprod 2000;15:604-7.
55. Klip H, Burger CW, de Kraker J, van Leeuwen FE. Risk of cancer in the offspring of women who underwent ovarian stimulation for IVF. Hum Reprod 2001;16:2451-8.
56. Brinton LA, Kruger Kjaer S, Thomsen BL, et al. Childhood tumor risk after treatment with ovulation-stimulating drugs. Fertil Steril 2004;4:1083-91.
57. Lerner-Geva L, Toren A, Chetrit A, et al. The risk for cancer among children of women who underwent in vitro fertilization. Cancer 2000;88:2845-7.
58. Schüz J, Kaatsch P, Kaletsch U, Meinert R, Michaelis J. Association of childhood cancer with factors related to pregnancy and birth. Int J Epidemiol 1999;28:631-9.
59. Olshan AF, Smith J, Cook MN, et al. Hormone and fertility drug use and the risk of neuroblastoma: A report from the Children's Cancer Group and the Pediatric Oncology Group. Am J Epidemiol 1999;150:930-8.
60. Petignat P, Vassilakos P, Campana A. Are fertility drugs a risk factor for persistent trophoblastic tumour? Hum Reprod. 2002;17:1610-5.